• Clinical Insights: July 14, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval Blincyto® (blinatumomab) – New Expanded Indication Approval – July 11, 2017 – Amgen announced that the U.S. Food and Drug… Read more »

  • RxStrategies Clinical Insights — August 2015 Issue 1

    Welcome to the August edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Odomzo® (sonidegib) July 24, 2015 — The U.S. Food and Drug Administration approved Odomzo® (sonidegib) to treat patients with locally advanced basal cell carcinoma that… Read more »

  • RxStrategies Clinical Insights — June/July Issue 1

    Welcome to the June/July edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Kengreal™ (cangrelor) June 22, 2015 — The U.S. Food and Drug Administration approved Kengreal™ (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood… Read more »

  • RxStrategies Clinical Insights – May 2015 Issue 2

    Welcome to May’s second edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Viberzi™ (eluxadoline) May 27, 2015 — Actavis plc announced Viberzi™ (eluxadoline) was approved by the Food and Drug Administration as a twice-daily, oral treatment for… Read more »

  • RxStrategies Clinical Insights – May 2015 Issue 1

    Welcome to the May edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Kybella™ (deoxycholic acid) April 29, 2015 – The U.S. Food and Drug Administration approved Kybella™ (deoxycholic acid), a treatment for adults with moderate-to-severe fat below… Read more »

  • RxStrategies Clinical Insights – April 2015 Issue 1

    Welcome to the April edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Corlanor® (ivabradine) April 15, 2015 – The U.S. Food and Drug Administration approved Corlanor® (ivabradine) to reduce hospitalization from worsening heart failure. Corlanor® is approved for use… Read more »

  • RxStrategies Clinical Insights – March Issue 2

    Welcome to the March second edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Anthrasil™ (Anthrax Immune Globulin Intravenous – Human) – New Drug Approval March 25, 2015 – The U.S. Food and Drug Administration approved… Read more »

  • RxStrategies Clinical Insights – January 2015, Issue 1

    Welcome to the January edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Savaysa™ (edoxaban tablets) January 8, 2015 — The U.S. Food and Drug Administration approved the anti-clotting drug Savaysa™ (edoxaban tablets) to reduce the risk of… Read more »

  • RxStrategies Clinical Insights – December 2014, Issue 1

    Welcome to the December edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Blincyto™ (blinatumomab) December 3, 2014 – The U.S. Food and Drug Administration approved Blincyto™(blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute… Read more »

  • RxStrategies Clinical Insights – November 2014, Issue 2

    Welcome to the second November edition of RxStrategies Clinical Insights, a concise communication to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approvals Lemtrada™ (alemtuzumab) November 14, 2014—The U.S. Food and Drug Administration has approved Lemtrada™ (alemtuzumab) as a disease-modifying therapy for people with relapsing forms of Multiple… Read more »